This week, the U.S. Department of Health and Human Services began drastically reducing its workforce across all of its agencies, including the Food and Drug Administration and National Institutes of Health. A fully functional FDA and NIH are critical to deepening knowledge of CF and advancing therapeutic developments. We issued a statement urging the U.S. Department of Health and Human Services to avoid sudden and sweeping cuts that would have a devastating impact on medical research and drug development for CF. We urge the Department of Health and Human Services to avoid cuts that eliminate essential agency expertise. We hope to work with the administration to strengthen the NIH and FDA’s ability to develop safe and effective new treatments for people with CF and advance American scientific innovation. (fb)

The International Journal of Neonatal Screening, an international, peer-reviewed journal on newborn screening and newborn medicine, recently published newborn screening recommendations for cystic fibrosis. These recommendations represent a significant milestone of the Foundation’s Newborn Screening Initiative, a multi-year effort to advance CF newborn screening and achieve better health outcomes for all babies born with the disease, regardless of background. (fb)